Radiopharm Theranostics Ltd (RADX) Form 6-K — Jul 24, 2026
Radiopharm Theranostics Limited announced a concurrent capital raise combining a U.S. registered direct offering and private placement with Australian institutional and retail investor offers to fund clinical development and working capital. In the United States, the company issued 1,281,646 American Depositary Shares at $3.16 per share for gross proceeds of approximately $4.1 million, accompanied by unregistered warrants to purchase an equivalent number of shares at $3.79 per share expiring in July 2029.
Key figures
- Gross Proceeds
- $4.1 million
- Offering Price
- 3.16
- Shares Offered
- 1281646
- Spp Target
- A$6 million
- Warrant Expiry
- July 31, 2029
- Warrant Exercise Price
- $3.79
- Total Estimated Proceeds
- ~US$13 million
- Austradian Placement Gross
- A$6.7 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.